FDA recommends inclusion of patients as young as 6 months - younger than Moleculin had proposed - to be allowed in the ...

Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to <16 years old with Friedreich ataxia, a rare neurodegenerative disorder BRAVE study will explore the ...

New intellectual property builds on Palvella’s multi-layered exclusivity strategy Patent term expected through at least 2038 ...